Advertisement

Early Fibrosis but Late Tumor Stage and Worse Outcomes in Hepatocellular Carcinoma Patients Without Hepatitis B or Hepatitis C

  • Po-Yao Hsu
  • Cheng-Ting Hsu
  • Ming-Lun Yeh
  • Chung-Feng Huang
  • Ching-I Huang
  • Po-Cheng Liang
  • Yi-Hung Lin
  • Ming-Yen Hsieh
  • Yu-Ju Wei
  • Meng-Hsuan Hsieh
  • Chia-Yen Dai
  • Zu-Yau Lin
  • Shinn-Cherng Chen
  • Jee-Fu HuangEmail author
  • Ming-Lung Yu
  • Wan-Long Chuang
Original Article

Abstract

Background and Aims

The features of non-viral, nonalcohol hepatocellular carcinoma (NBNC-HCC) remain elusive. The aim of this study was to investigate this clinical characteristics and overall survival of NBNC-HCC compared to hepatitis B- (HBV-HCC) and hepatitis C-related (HCV-HCC) HCC.

Methods

We analyzed the etiologies, fibrosis stages, clinical data, and outcomes of newly diagnosed patients with HCC.

Results

A total of 1777 HCC patients were recruited, including 332 patients with NBNC-HCC, 682 patients with HBV-HCC, 680 patients with HCV-HCC, and 83 patients with HBV/HCV HCC. Patients with NBNC-HCC were older (69.9 ± 11.9 years). Patients with NBNC-HCC exhibited a higher prevalence of diabetes (43.9%) compared to the HBV-HCC (27.1%, p < 0.05) and HCV-HCC (30.2%, p < 0.05) groups. Compared to patients from the viral-related HCC groups, patients with NBNC-HCC exhibited a significantly lower fibrosis stage. NBNC-HCC patients exhibited a higher proportion of Barcelona Clinic Liver Cancer (BCLC) classification stage C and stage D compared to patients from the HBV-HCC and HCV-HCC groups. With a mean of 2.33 ± 2.31 years of follow-up, the median survival of patients with NBNC-HCC was 1.75 (95% CI 1.33–2.17) years, which was significantly lower than that of patients with HBV-HCC (p = 0.041) and HCV-HCC (p < 0.001).

Conclusions

Patients with NBNC-HCC have a higher risk of diabetes than patients with HCC of viral etiologies. Although patients with NBNC-HCC exhibited a milder fibrosis stage, their more advanced HCC stages and worse overall survival should be taken into consideration in clinical care.

Keywords

Hepatocellular carcinoma Liver fibrosis Cancer staging Nonalcoholic fatty liver disease 

Notes

Acknowledgments

This study was supported partly by grants from The Ministry of Science and Technology, Taiwan (MOST104-2314-B-037-078-MY3, 107-2314-B-037-082-MY3), and Kaohsiung Medical University Hospital (S10606, S10709, KMUH106-6R07). The authors thank secretary help from Taiwan Liver Research Foundation (TLRF). The foundation did not influence how the study was conducted or the approval of the manuscript. The authors also thank Dr. Tyng-Yuan Jang and Dr. Ta-Ya Lin for their active contribution in revising the manuscript.

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of Institutional Review Board of Kaohsiung Medical University Chung-Ho Memorial Hospital (IRB Number: KMUHIRB-E(II)-20180281) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Nishikawa H, Osaki Y. Non-B, non-C hepatocellular carcinoma (Review). Intern J Oncol. 2013;43:1333–1342.CrossRefGoogle Scholar
  2. 2.
    Cho EJ, Kwack MS, Jang ES, et al. Relative etiological role of prior hepatitis B virus infection and nonalcoholic fatty liver disease in the development of non-B non-C hepatocellular carcinoma in a hepatitis B-endemic area. Digestion. 2011;84:17–22.CrossRefGoogle Scholar
  3. 3.
    Utsunomiya T, Shimada M. Molecular characteristics of non-cancerous liver tissue in non-B non-C hepatocellular carcinoma. Hepatol Res. 2011;41:711–721.CrossRefGoogle Scholar
  4. 4.
    Lu SN, Su WW, Yang SS, et al. Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan. Intern J Cancer. 2006;119:1946–1952.CrossRefGoogle Scholar
  5. 5.
    Kimura T, Kobayashi A, Tanaka N, et al. Clinicopathological characteristics of non-B non-C hepatocellular carcinoma without past hepatitis B virus infection. Hepatol Res. 2017;47:405–418.CrossRefGoogle Scholar
  6. 6.
    Tateishi R, Okanoue T, Fujiwara N, et al. Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study. J Gastroenterol. 2015;50:350–360.CrossRefGoogle Scholar
  7. 7.
    Suzuki Y, Ohtake T, Nishiguchi S, et al. Survey of non-B, non-C liver cirrhosis in Japan. Hepatol Res. 2013;43:1020–1031.PubMedGoogle Scholar
  8. 8.
    Kim SK, Marusawa H, Eso Y, et al. Clinical characteristics of non-B non-C hepatocellular carcinoma: a single-center retrospective study. Digestion. 2011;84:43–49.CrossRefGoogle Scholar
  9. 9.
    Nakagawa S, Wei L, Song WM, et al. Molecular liver cancer prevention in cirrhosis by organ transcriptome analysis and lysophosphatidic acid pathway inhibition. Cancer Cell. 2016;30:879–890.CrossRefGoogle Scholar
  10. 10.
    Wakiyama S, Matsumoto M, Haruki K, et al. Clinical features and outcome of surgical patients with non-B non-C hepatocellular carcinoma. Anticancer Res. 2017;37:3207–3213.PubMedGoogle Scholar
  11. 11.
    Nishio T, Hatano E, Sakurai T, et al. Impact of hepatic steatosis on disease-free survival in patients with non-B non-C hepatocellular carcinoma undergoing hepatic resection. Ann Surg Oncol. 2015;22:2226–2234.CrossRefGoogle Scholar
  12. 12.
    Imura S, Shimada M, Utsunomiya T, et al. Clinicopathological characteristics of patients with non-B non-C hepatocellular carcinoma: a special reference to metabolic syndrome. Hepato-gastroenterology. 2014;61:129–135.PubMedGoogle Scholar
  13. 13.
    Okuda Y, Mizuno S, Shiraishi T, et al. Clinicopathological factors affecting survival and recurrence after initial hepatectomy in non-B non-C hepatocellular carcinoma patients with comparison to hepatitis B or C virus. BioMed Res Intern. 2014;2014:975380.CrossRefGoogle Scholar
  14. 14.
    Nishikawa H, Arimoto A, Wakasa T, Kita R, Kimura T, Osaki Y. Comparison of clinical characteristics and survival after surgery in patients with non-B and non-C hepatocellular carcinoma and hepatitis virus-related hepatocellular carcinoma. J Cancer. 2013;4:502–513.CrossRefGoogle Scholar
  15. 15.
    Kaneda K, Kubo S, Tanaka H, et al. Features and outcome after liver resection for non-B non-C hepatocellular carcinoma. Hepato-gastroenterology. 2012;59:1889–1892.PubMedGoogle Scholar
  16. 16.
    Chang IC, Huang SF, Chen PJ, et al. The hepatitis viral status in patients with hepatocellular carcinoma: a study of 3843 patients from Taiwan liver cancer network. Medicine. 2016;95:e3284.CrossRefGoogle Scholar
  17. 17.
    Yeh ML, Huang CI, Huang CF, et al. The impact of an additional extra-hepatic primary malignancy on the outcomes of patients with hepatocellular carcinoma. PLoS ONE. 2017;12:e0184878.CrossRefGoogle Scholar
  18. 18.
    Kuo YH, Kee KM, Wang JH, et al. Association between chronic viral hepatitis and metabolic syndrome in southern Taiwan: a large population-based study. Aliment Pharmacol Ther. 2018;48:993–1002.CrossRefGoogle Scholar
  19. 19.
    Kwak HW, Park JW, Koh YH, Lee JH, Yu A, Nam BH. Clinical characteristics of patients with cryptogenic hepatocellular carcinoma in a hepatitis B virus-endemic area. Liver Cancer. 2016;5:21–36.CrossRefGoogle Scholar
  20. 20.
    Tokushige K, Hashimoto E, Horie Y, Taniai M, Higuchi S. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey. J Gastroenterol. 2011;46:1230–1237.CrossRefGoogle Scholar
  21. 21.
    Nagaoki Y, Hyogo H, Aikata H, et al. Recent trend of clinical features in patients with hepatocellular carcinoma. Hepatol Res. 2012;42:368–375.CrossRefGoogle Scholar
  22. 22.
    Chen CH, Huang GT, Yang PM, et al. Hepatitis B- and C-related hepatocellular carcinomas yield different clinical features and prognosis. Euro J Cancer. 2006;42:2524–2529.CrossRefGoogle Scholar
  23. 23.
    Oh KC, Park SH, Park JC, et al. Is the prevalence of cryptogenic hepatocellular carcinoma increasing in Korea? Korean J Gastroenterol. 2005;45:45–51.PubMedGoogle Scholar
  24. 24.
    Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84.CrossRefGoogle Scholar
  25. 25.
    Ma WL, Lai HC, Yeh S, Cai X, Chang C. Androgen receptor roles in hepatocellular carcinoma, fatty liver, cirrhosis and hepatitis. Endocr Relat Cancer. 2014;21:R165–R182.CrossRefGoogle Scholar
  26. 26.
    Jun TW, Yeh ML, Yang JD, et al. More advanced disease and worse survival in cryptogenic compared to viral hepatocellular carcinoma. Liver Intern. 2018;38:895–902.CrossRefGoogle Scholar
  27. 27.
    Karagozian R, Derdak Z, Baffy G. Obesity-associated mechanisms of hepatocarcinogenesis. Metabolism. 2014;63:607–617.CrossRefGoogle Scholar
  28. 28.
    Mittal S, Sada YH, El-Serag HB, et al. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol. 2015;13:594-601.e1.CrossRefGoogle Scholar
  29. 29.
    Piscaglia F, Svegliati-Baroni G, Barchetti A, et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study. Hepatology. 2016;63:827–838.CrossRefGoogle Scholar
  30. 30.
    Ohkura Y, Sasaki K, Matsuda M, Hashimoto M, Watanabe G. Long-term prognosis after resection of cryptogenic hepatocellular carcinoma. BMC Surg. 2015;15:115.CrossRefGoogle Scholar
  31. 31.
    Takeishi K, Maeda T, Shirabe K, et al. Clinicopathologic features and outcomes of non-B, non-C hepatocellular carcinoma after hepatectomy. Ann Surg Oncol. 2015;22:S1116–S1124.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Po-Yao Hsu
    • 1
  • Cheng-Ting Hsu
    • 1
  • Ming-Lun Yeh
    • 1
    • 2
    • 3
  • Chung-Feng Huang
    • 1
    • 2
    • 3
  • Ching-I Huang
    • 1
    • 2
    • 3
  • Po-Cheng Liang
    • 1
    • 2
  • Yi-Hung Lin
    • 1
  • Ming-Yen Hsieh
    • 1
  • Yu-Ju Wei
    • 1
  • Meng-Hsuan Hsieh
    • 1
    • 3
    • 4
  • Chia-Yen Dai
    • 1
    • 2
    • 3
  • Zu-Yau Lin
    • 1
    • 3
  • Shinn-Cherng Chen
    • 1
    • 3
  • Jee-Fu Huang
    • 1
    • 2
    • 3
    • 5
    Email author
  • Ming-Lung Yu
    • 1
    • 2
    • 3
    • 5
  • Wan-Long Chuang
    • 1
    • 2
    • 3
  1. 1.Hepatobiliary Division, Department of Internal MedicineKaohsiung Medical University HospitalKaohsiungTaiwan
  2. 2.Graduate Institute of Clinical MedicineKaohsiung Medical UniversityKaohsiungTaiwan
  3. 3.Faculty of Internal Medicine, College of MedicineKaohsiung Medical UniversityKaohsiungTaiwan
  4. 4.Department of Preventive MedicineKaohsiung Medical University HospitalKaohsiungTaiwan
  5. 5.Centre for Liquid Biopsy and Cancer Research CentreKaohsiung Medical UniversityKaohsiungTaiwan

Personalised recommendations